天圣制药集团股份有限公司关于变更签字会计师的公告

Core Viewpoint - The company has announced a change in its signing accountant for the 2025 annual audit, appointing Liu Wei to replace Yang Siqi due to the latter's work adjustment [1][3]. Group 1: Change of Signing Accountant - The company has retained Beijing Xinghua Accounting Firm for the 2025 financial statement and internal control audit [1]. - Liu Wei has been appointed as the new signing accountant, bringing experience from his work with listed companies since 2022 [3]. - The transition of responsibilities has been orderly, ensuring no adverse impact on the audit work for the 2025 financial statements [4]. Group 2: Risk Warning and Regulatory Actions - The company's stock has been under other risk warnings since June 5, 2019, due to allegations against the controlling shareholder for misappropriating company funds [6][7]. - The company received administrative penalty notices from the Chongqing Securities Regulatory Bureau on September 12 and November 7, 2025, related to false disclosures in financial reports [8]. - The controlling shareholder, Liu Qun, was found to have misappropriated a total of 125,074,926 yuan, which has been fully repaid as of April 8, 2021 [10].